Advisory Panel Meeting Menu Includes Self-Selection Risk/Benefit Evaluation
This article was originally published in The Tan Sheet
Executive Summary
FDA's Nonprescription Drugs Advisory Committee will tackle issues such as weighing the risks of self-selection failures against the benefit of successes when the panel convenes Sept. 25 to discuss OTC drug consumer behavior trials